Palo Alto, Calif.-based Theranos is standing by 99 percent of its blood test results.
Theranos retracted two years of tests conducted on its proprietary "Edison" device last month and it is now saying these tens of thousands of voided or corrected tests account for less than 1 percent of results it has provided patients, according to Bloomberg.
Theranos spokeswoman Brooke Buchanan also told Bloomberg these revisions were made out of "an abundance of caution," and all affected patients have been notified. The reason the company decided withdraw the tests was because they didn't meet current lab manager standards, Ms. Buchanan also told Bloomberg.
While lawsuits mount — the company now faces three potential consumer action lawsuits — Theranos is continuing to move full speed ahead. It is planning to grow its staff 20 percent and open a new lab in Harrisburg, Pa. At the end of next month, it plans to present peer reviewed studies of its technology at the American Association for Clinical Chemistry annual meeting, according to Bloomberg. Theranos' peer reviewed studies have been long-awaited by the healthcare industry, though some experts now have doubts the information will be able to save the company's reputation, Bloomberg reported.
Read the full report here.
More articles on leadership and management:
Why don't more CEOs endorse presidential candidates?
Viewpoint: Hillary Clinton's Medicare expansion plan incongruent with ACA
It's time for hospital executives to pay attention to social media